Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making.
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
This program has been made available online.
Review key slides on the interplay of COVID-19 and viral hepatitis and review expert strategies for managing chronic liver disease in the COVID-19 era
Clinical Care Options (CCO) commentary by Dr. Dominique Braun on the results of the Swiss HCVree Trial: HCV testing, treatment, and counseling in MSM with HIV and HCV
Limitations of the APASL guidelines and potential role of using HBcrAg for treatment candidacy and HCC screening, from Clinical Care Options (CCO)
Dr. Jean-Michel Pawlotsky: guidance from EASL on the treatment of patients with HBV and cirrhosis, from Clinical Care Options (CCO)